| SESSION 2: Chemistry Protecting Health | ||||
| Chairs | ||||
| G. Ronsisvalle | ||||
| SCI Pharmaceutical Chemistry Division, President | ||||
| Universitą di Catania, Catania, Italy | ||||
| e-mail: giuseppe.ronsisvalle@unict.it | ||||
| P.W. Erhardt | ||||
| IUPAC Chemistry and Human Health Division, President | ||||
| University of Toledo, College of Pharmacy, Toledo, OH 43606-3390, USA | ||||
| e-mail: paul.erhardt@utoledo.edu | ||||
| TOPIC TITLE | Analog-Based Drug Design | |||
| Monday 06 | evening | Chair: J. Fischer | ||
| speaker | title | |||
| key note | 17:00-17.40 | J. Senn-Bilfinger | Analogue-based design of gastric acid anti-secretory agents. Past and present | |
| oral | 17:40-18.00 | J. Fischer | Optimising drug therapy by analogs | |
| oral | 18:00-18:20 | S. Bachurin | Computational approaches to synthetic design, discovery and development of new neuroactive glutamate receptor ligands | |
| oral | 18:20-18:40 | O. Garcģa-Mellado | Synthesis of new of dibenzo[b,e][1,4]diazepin-1-ones. Spectroscopy and biological activity | |
| TOPIC TITLE | Nomenclature, properties and units in Clinical Chemistry | |||
| Tuesday 07 | afternoon | Chair: F. Pontet | ||
| speaker | title | |||
| key note | 14.30-15.10 | R. Dybkęr | Description of chemical systems by their properties | |
| oral | 15:10-15:30 | U. Magdal | Nationwide use of a terminology for clinical laboratory communication | |
| oral | 15:30-15:50 | G. Nordin | Glycohaemoglobin formal description of the quantity as measured by the reference measurement procedure | |
| oral | 15.50-16.10 | L. Campanella | Determination of immunoglobulins G in milk and human serum by means of an immunobiosensor fitted with an enzymatic probe as detector | |
| oral | 16:10-16:30 | Z. Chai | Advanced nuclear analytical techniques for nanotoxicology study | |
| TOPIC TITLE | Cancer Chemotherapeutic Agents | |||
| Wednesday 08 | morning | Chair: R. Ganellin | ||
| speaker | title | |||
| key note | 10:30-11:10 | M. Stevens | Chemistry-driven anticancer drug discovery | |
| oral | 11:10-11:50 | A. Ganesan | Potent cyclic peptide and depsipeptide histone deacetylase inhibitors | |
| oral | 11:50-12:10 | R. Castanheiro | Prenylation of 1,3-dihydroxy-2-methylxanthone: improvements on the growth inhibitory activity against MCF-7 cell line | |
| oral | 12:10-12:30 | A.J. Nuńez-Selles | The paradox of natural products as pharmaceuticals | |
| TOPIC TITLE | Multi-Target Drugs | |||
| Thursday 09 | morning | Chair: G. Ronsisvalle | ||
| speaker | title | |||
| key note | 10:30-11:10 | A. Gasco | Multi-target drugs: focus on NO-donor hybrid drugs | |
| oral | 11:10-11:50 | F. Wakenhut | Discovery of PF-184298, a dual serotonin/noradrenaline reuptake inhibitor | |
| oral | 11:50-12:30 | P. Erhardt | Directing Drug Distribution: avoiding multidrug resistance while targeting cancer cells | |
| TOPIC TITLE | Prodrugs and Soft Drugs | |||
| Thursday 09 | afternoon | Chair: H. Ando | ||
| speaker | title | |||
| keynote | 14:30-15:10 | N. Bodor | Recent Developments in Retrometabolic Drug Design and Targeting Strategies | |
| oral | 15:10-15:50 | C. Becker | Retro-metabolic approach to the design of ATI-5923, a vitamin K epoxide reductase inhibitor analog of warfarin | |
| oral | 15:50-16:30 | W. A. Wlassoff | Prodrug approach to the treatment of cancer: The targeted generation of free oxygen radicals promoting apoptotic death of cancer cells | |